2021 FDA approvals - Nature
https://www.nature.com/articles/d41573-022-00001-9
Vaccine VictoriesCancer CapstonesAlzheimer’s AcrimonyOther Standouts With the approval of Novartis and Alnylam’s inclisiran, a fourth siRNA-based drug has arrived. This modality harnesses RNA interferenceto reduce the expression of therapeutic targets. Inclisiran inhibits PCSK9 to lower LDL-cholesterol. The FDA approved two antibodies that target PCSK9 — Regeneron and Sanofi’s alirocumab and Amgen’s evolocumab — in ...
With the approval of Novartis and Alnylam’s inclisiran, a fourth siRNA-based drug has arrived. This modality harnesses RNA interferenceto reduce the expression of therapeutic targets. Inclisiran inhibits PCSK9 to lower LDL-cholesterol. The FDA approved two antibodies that target PCSK9 — Regeneron and Sanofi’s alirocumab and Amgen’s evolocumab — in ...
DA: 49 PA: 88 MOZ Rank: 41